PID Antibody
Code | Size | Price |
---|
PSI-2443-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-2443-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
PID Antibody: PID, MTA1L1, PID, Metastasis-associated protein MTA2, Metastasis-associated 1-like 1, MTA1-L1 protein
Application Note:
PID antibody can be used for detection of PID by Western blot at 1 μg/mL. Antibody can also be used for immunocytochemistry starting at 10 μg/mL and Immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
PID Antibody: The p53 tumor-suppressor gene integrates numerous signals that control cell life and death. Several novel molecules involved in p53 pathway, including Chk2, p53R2, p53AIP1, Noxa, PIDD, and PID/MTA2, were recently discovered. The transcriptional activity of p53 is modulated by protein stability and acetylation. PID/MTA2, also termed MTA1-L1, was found to be a subunit of nucleosome remodeling and deacetylating (NRD/NuRD) complex. PID/MTA2 modulates the enzymatic activity of the histone deacetylase complex and its expression reduces the levels of acetylated p53. Deacetylation of p53 by PID/MTA2 represses p53-dependent transcriptional activation and modulates p53-mediated cell growth arrest and apoptosis. PID/MTA2 is ubiquitously expressed in human tissues.
Background References:
- Matsuoka S, Huang M, and Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282:1893-7.
- Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404:42-9.
- Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288:1053-8.
- Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
Buffer:
PID Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
PID antibody was raised against a 17 amino acid peptide near the carboxy terminus of human PID.
The immunogen is located within the last 50 amino acids of PID.
The immunogen is located within the last 50 amino acids of PID.
NCBI Gene ID #:
9219
NCBI Official Name:
metastasis associated 1 family, member 2
NCBI Official Symbol:
MTA2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 73 kDa
Observed: 75 kDa
Observed: 75 kDa
Protein Accession #:
AAG02241
Protein GI Number:
9931638
Purification:
PID Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
PID antibody is predicted to not cross-react with MTA2
Swissprot #:
O94776
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | PID Peptide | PSI-2443P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|